# OnCo record lamassu-biotech (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/lamassu-biotech/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "lamassu-biotech" ;
  schema:name "Lamassu Biotech"@en ;
  schema:alternateName "Lamassu Bio Inc"@en ;
  schema:description "Lamassu Biotech is testing a tablet that switches back on p53, a protein that normally stops cancer growth, in tumours where p53 itself is still intact."@en ;
  schema:url <https://onco.cc/companies/lamassu-biotech/>, <https://www.lamassubiotech.com/> ;
  schema:dateModified "2026-10-29"^^xsd:date ;
  schema:citation <https://www.lamassubiotech.com/>, <https://www.lamassubiotech.com/2026/10/26/lamassu-biotech-presents-initial-safety-and-pharmacokinetic-data-for-mdm2-inhibitor-sa53-from-first-in-human-phase-1-2a-study-at-esmo-congress-2026/>, <https://www.lamassubiotech.com/news-releases/> ;
  schema:addressCountry "US" ;
  onco:sections <https://onco.cc/fronts/targeted-therapy/> ;
  onco:technologies <https://onco.cc/technologies/mdm2-inhibitors/> ;
  onco:targets <https://onco.cc/targets/mdm2/> ;
  onco:trials <https://onco.cc/trials/nct06578624/> .